Captrust Financial Advisors Sells 22,765 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Captrust Financial Advisors decreased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 75.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,562 shares of the biopharmaceutical company's stock after selling 22,765 shares during the period. Captrust Financial Advisors' holdings in TG Therapeutics were worth $228,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. Quadrant Capital Group LLC raised its holdings in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares in the last quarter. Blue Trust Inc. raised its holdings in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC bought a new position in TG Therapeutics in the 4th quarter worth $75,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Up 1.0%

TGTX stock traded up $0.33 during trading on Friday, hitting $34.57. 1,042,767 shares of the stock traded hands, compared to its average volume of 2,989,933. TG Therapeutics, Inc. has a 1 year low of $15.16 and a 1 year high of $46.48. The firm's 50 day moving average is $38.13 and its two-hundred day moving average is $34.22. The stock has a market cap of $5.49 billion, a price-to-earnings ratio of -345.67 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business's revenue for the quarter was up 90.4% compared to the same quarter last year. During the same period last year, the company posted ($0.07) earnings per share. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on TGTX. HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Wall Street Zen raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.